Introduction: Diagnostic guidelines for Tuberculosis (TB) in HIV infected patients previously relied on microscopy where the value of initial antibiotic treatment for exclusion of pulmonary TB (PTB) was limited. New guidelines rely on the Xpert MTB Rif test (Xpert). However, the value of the antibiotic treatment remains unclear particularly in individuals who are smear-negative and Xpert-negative-given Xpert has only moderate sensitivity for smear-negative PTB. We assessed an algorithm involving initial treatment with antibiotics prior empiric TB treatment in HIV patients with presumptive PTB who were both smear and Xpert negative. Methods: We performed a prospective study with six month follow-up to establish patient response to a course of broad spectrum antibiotics prior empiric TB treatment between March 2012 and June 2013. We calculated the proportion of patients who responded to the antibiotic treatment and those who did not. We computed the crude and adjusted odds ratios with their 95% confidence intervals, for response to the antibiotic treatment on various patient characteristics. We report treatment outcomes for patients who received broad spectrum antibiotics only or who were initiated empiric TB treatment. Results: Our cohort comprised 162 smearnegative and Xpert-negative patients, of whom 59% (96 of 162) were female, 81% (131 of 162) were on antiretroviral therapy (ART) for a median of 8.7 months. Overall, 88% (141 of 160) responded to the antibiotic treatment, 8% (12 of 160) got empiric TB treatment and 4% (7 out of 160) were treated for other respiratory disease. The odds of improvement on antibiotics were lower in patients with advanced HIV disease than in patients with early HIV disease. Adjusted odds ratios were significant for HIV clinical stage (AOR; 0.038,) and duration on ART (AOR; 1.038,).
Introduction
Tuberculosis (TB) with HIV co-infection is highly prevalent in subSaharan Africa, accounting for seventy-five percent of HIVassociated TB globally [1] . Traditionally, TB diagnosis in the region relies on sputum smear microscopy. However, TB microscopy misses many patients especially if they are infected with HIV [2] .
Thus, smear-negative TB is a common clinical problem and the practice of empiric TB treatment is equally common [3, 4] . Since
2010, the World Health Organization (WHO) has recommended
Xpert MTB/RIF test (Xpert) as the primary diagnostic for HIVassociated TB or where resources are limited, as a follow-on test to TB microscopy. Xpert has been scaled-up in numerous global settings since that time [5, 6] . However, Xpert has only moderate (67%) sensitivity for smear-negative pulmonary TB and a negative Xpert result is insufficient therefore to rule out active pulmonary TB (PTB) [7, 8] . Existing clinical algorithms for management of ambulatory Xpert negative patients include further investigation for other aetiologies of respiratory disease or extra-pulmonary TB (EPTB) with the assistance of quality chest X-ray, repeat Xpert or culture [9, 10] . These algorithms however, are lengthy to implement, requiring patients to make three or more visits with high potential for patient drop-out during the diagnostic process [11] .
Furthermore, quality chest X-ray is not accessible in many peripheral or even referral health facilities. But even when chest X-ray is performed, it does not provide a microbiological diagnosis of TB and cannot therefore, be relied upon for a definitive diagnosis of the disease [12] . On the other hand, Mycobacterial culture is undertaken at central level laboratories and results are seldom available in a clinically relevant timeframe [13] . While a repeat Xpert test although attractive, is currently very expensive to implement in routine patient care [14] . Thus, clinicians in settings where TB-HIV co-infection is prevalent, still face the dilemma of what to do with smear-negative and Xpert negative patients. Commonly, they treat such patients for TB on basis of clinician decision [15, 16] . In the era when TB diagnostic algorithms relied primarily on microscopy, the value of antibiotic treatment in HIV patients with presumptive TB was limited as response to the antibiotics did not exclude TB [17] . While several studies have researched the diagnostic accuracy of the Xpert, there is limited evidence for the use of antibiotic treatment in the diagnosis process of TB in the era of Xpert [18] . In this study, we report on outcomes in our setting in Uganda, following the implementation of an algorithm to manage HIVinfected individuals with presumptive TB who were smear-negative and Xpert-negative. The algorithm involved initial treatment with broad spectrum antibiotics prior a decision to initiate empiric TB treatment. This strategy was previously used before to increase diagnostic accuracy of TB in high HIV prevalent settings [19] . Since the Xpert has moderate sensitivity for smear-negative TB which is common in this patient group, the question of response to initial antibiotic treatment is an important one to study in settings with limited diagnostic microbiology.
Methods

Study design and setting
This prospective cohort study was conducted at the Mulago-Immune Suppression Syndrome (Mulago-ISS) clinic which is located at the campus of Mulago National Referral Hospital in Kampala, Uganda. Xpert negative were enrolled into the study. We excluded patients on quinolone medication during the enrollment period.
Study procedures
Participants provided a spot and early morning sputum sample which were examined by FM. Samples which were FM negative (smear-negative) were examined further using a one-off Xpert test and combined solid and liquid TB culture as part of a research procedure [20] . If the Xpert test was positive, TB treatment was initiated. Patients whose Xpert test results were negative for TB were treated with oral broad spectrum antibiotics using macrolides such as azithromycin, or cephalosporins such as cefuroxime. We did not use quinolones as they used to treat TB. Patients were asked to return for review after two weeks or earlier if their symptoms worsened. At review, the clinical status of the patients was assessed to establish response (reported by patients as absence or presence of symptoms) to the antibiotic treatment. If the patient did not respond to the antibiotic treatment, other investigations when present, such as chest X-ray or abdominal ultra-sound or microscopy exam of lymph node aspirate or biopsy were done to exclude EPTB and other etiologies of respiratory disease. Patients diagnosed with other respiratory diseases were referred to specialist clinics in the hospital and no further follow-up was done. If no other diagnosis was made, the patients were initiated on standard anti-TB treatment empirically. This comprised an initial phase of two months of daily rifampicin, isoniazid, pyrazinamide and ethambutol (all the Xpert negative patients were presumed to be susceptible to Rifampicin), followed by a four months continuation phase of daily rifampicin and isoniazid at a specialized out-patient TB/HIV clinic.
Patients were reviewed after two weeks initially and every 4 weeks subsequently to monitor clinical status and adherence to treatment.
All the patients were followed up for six months.
Study definitions
We defined the baseline CD4 lymphocyte counts as those that were recorded closest to the date when patients were enrolled into the study, with a maximum of 6 months prior. Response to antibiotic treatment was reviewed each month and was defined as being symptom free at six months after the course of antibiotic treatment.
Response to empiric TB treatment was defined as being symptom free at six months following initiation of the TB treatment. Duration on ART was defined as the period from the date of initiation of ART at MJAP to the date when the patient was enrolled into the study.
Patients were defined as lost to follow-up if they did not attend the clinic for more than 90 days from the day the patient's sputum sample was collected. Individuals recorded as dead in the patient charts were confirmed through telephone call to their next of kin.
Data collection
A standardized data collection form was used to collect individual patient data at presentation (baseline) and at month six. Socio- 
Data analysis
The mean and median were used to summarize numerical data.
Frequencies and proportions were used to summarize categorical data. The T-test was used to compare normally distributed numerical data and the Mann-Whitney rank-sum test was used to compare non-normally distributed numerical data. The Chi-squared or Fisher's exact tests were used to compare categorical data. We compared the odds of response to antibiotics to the odds of noresponse to the antibiotics (inclusive of those diagnosed with other respiratory diseases) to obtain crude odds ratios for each patient characteristic. Multivariate logistic regression using the crude odds ratios was performed to obtain adjusted odds ratios for characteristics with p values of less than 0.2 and those with a biological plausibility to influence response to antibiotic treatment.
Ethical considerations
The Uganda national Council for Science and Technology provided the ethical approval for the study (HS 1214).
Results
General patient characteristics
A total of 162 smear-negative and Xpert-negative patients were enrolled. Their general characteristics are summarized in Table 1 (Table 3) . Of the cultures requested, reports were provided for 68% (110/162) of the patients. Nearly all the missing reports were for patients who received antibiotic treatment only. The culture reports were negative for TB in all patients who responded to antibiotic treatment and in patients diagnosed with other respiratory illnesses.
Of the twelve patients who got empiric TB treatment, only one was culture positive, eight were culture negative and three were undetermined because the cultures were either contaminated or the report was missing. likely to complete short-course antibiotics regimens as prescribed, which is one strategy to decrease antibiotic resistance [24] . In addition, the effectiveness of the antibiotics could be maintained if they are chosen wisely. For example, in our study, we excluded the use of quinolones because they are used in second line treatment for TB, and their routine use is associated with delayed treatment and resistance in TB [25] . To facilitate wise choice of the antibiotics, clinicians need to follow existing recommendations to prescribe fewer broad spectrum antibiotics based on standard treatment guidelines. These guidelines in turn need periodic and regular review using data from surveillance of bacterial resistance and antibiotic use [26] .
Our strategy could be useful in our setting or similar other settings because laboratories may not cope with the influx of clinical specimens for both TB diagnosis and follow-up examinations. This strategy could therefore save resources, that would otherwise be consumed by performing additional tests and procedures for patients in whom the majority would eventually not have TB as shown by one study from the same study area [27] . This study and another recent one, showed that the common bacterial infections in HIV patients, are susceptible to broad spectrum antibiotics and therefore are useful in routine patient care [28] . Moreover, it was shown also, that the early clinical consequences of false-negative Xpert tests were not grave and that rapid empiric TB treatment may not be necessary in patients with Xpert negative results [21] . Our strategy involved two clinic visits by patients before the decision to treat for TB was taken. Few patients (3 out of 162) were not accounted for in the diagnostic pathway meaning the strategy could be feasible. This is useful because lengthy algorithms are poorly implemented by clinicians and are associated with high patient lossto-follow-up and poor patient outcomes [11, 29] . Our study was done in a setting where Xpert had a high negative predictive value (those who were negative by Xpert were unlikely to have PTB) and therefore, cure from a course of antibiotics was high. The results are only applicable to similar settings where Xpert has a high negative predictive value. We acknowledge the small size of our study, which could result in inconsistent measures of association.
Second, we studied a highly selected out-patient HIV population where the majority (81%) of the individuals were on ART compared to 62% in the general adult population in Uganda setting [30] .
These results may therefore not be generalized to hospitalized patients or to populations where ART coverage is low. Third, our findings could also be cofounded by co-morbidities such as smoking status, diabetes, adherence to the prescribed medicines or baseline CD4 versus CD4 counts at six months, which we did not analyse as these data were not collected. Other predictive factors not collected included symptom intensity, haemoglobin concentration, serum Creactive protein and body mass index, Therefore, the range of possible factors influencing patient outcomes in our study was not exhaustive. Fourth, we did not ascertain if the patients whose cultures were contaminated and were empirically treated for TB, did not actually have disease. Additional sample collection and culture would have been useful to confirm if they had TB or not. However, the results were not received in time to collect another sample before treatment was initiated.
Conclusion
The majority of HIV patients with presumptive PTB with smearnegative and Xpert negative results in our clinic setting improved on the antibiotic treatment and did not require empiric TB treatment. 
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